{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:31:27Z","timestamp":1785148287508,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04922-9","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:43:40Z","timestamp":1783399420000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Successful oral desensitization to temozolomide in a patient with immediate hypersensitivity reaction"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-6433","authenticated-orcid":false,"given":"Ece","family":"\u015eahino\u011flu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7769-2592","authenticated-orcid":false,"given":"Muhittin","family":"Akarsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3076-1048","authenticated-orcid":false,"given":"Selma","family":"Yal\u00e7\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8806-2764","authenticated-orcid":false,"given":"Dil\u015fad","family":"Mungan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4188-0959","authenticated-orcid":false,"given":"Zeynep","family":"Celebi Sozener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"issue":"19 Pt 1","key":"4922_CR1","doi-asserted-by":"publisher","first-page":"6767","DOI":"10.1158\/1078-0432.CCR-05-0722","volume":"11","author":"MH Cohen","year":"2005","unstructured":"Cohen MH, Johnson JR, Pazdur R (2005) Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res 11(19 Pt 1):6767\u20136771. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-0722","journal-title":"Clin Cancer Res"},{"key":"4922_CR2","unstructured":"FDA approves new and updated indications for temozolomide under Project Renewal. News release. September 14, (2023)"},{"issue":"7","key":"4922_CR3","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.3390\/curroncol31070296","volume":"31","author":"M Jezierza\u0144ski","year":"2024","unstructured":"Jezierza\u0144ski M, Nafalska N, Stopyra M, Furgo\u0142 T, Miciak M, Kabut J, Gisterek-Grocholska I (2024) Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme-A Literature Review and Clinical Outcomes. Curr Oncol 31(7):3994\u20134002. https:\/\/doi.org\/10.3390\/curroncol31070296","journal-title":"Curr Oncol"},{"issue":"4","key":"4922_CR4","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.3390\/molecules14041561","volume":"14","author":"GV Koukourakis","year":"2009","unstructured":"Koukourakis GV, Kouloulias V, Zacharias G, Papadimitriou C, Pantelakos P, Maravelis G, Fotineas A, Beli I, Chaldeopoulos D, Kouvaris J (2009) Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article. Molecules 14(4):1561\u20131577. https:\/\/doi.org\/10.3390\/molecules14041561","journal-title":"Molecules"},{"issue":"1","key":"4922_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.25259\/IJDVL_754_2021","volume":"89","author":"H Mehta","year":"2023","unstructured":"Mehta H, Gendle CS, Kumaran MS, Vinay K (2023) Temozolomide-induced drug rash with eosinophilia and systemic symptoms syndrome. Indian J Dermatol Venereol Leprol 89(1):160. https:\/\/doi.org\/10.25259\/IJDVL_754_2021","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"4922_CR6","doi-asserted-by":"publisher","unstructured":"Deluche E, Leobon S, Touraine F, Clav\u00e8re P (2014) Two cases of cutaneous drug eruption associated with temozolomide therapy for glioblastoma. Curr Oncol 21(6). https:\/\/doi.org\/10.3747\/co.21.2133. p. e779-81","DOI":"10.3747\/co.21.2133"},{"issue":"3","key":"4922_CR7","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/10781552211062569","volume":"28","author":"A Ambur","year":"2022","unstructured":"Ambur A, Ambur L, Khan L, Nathoo R (2022) Drug-induced hypersensitivity syndrome following temozolimide for glioblastoma multiforme and the role of desensitization therapy. J Oncol Pharm Pract 28(3):733\u2013735. https:\/\/doi.org\/10.1177\/10781552211062569","journal-title":"J Oncol Pharm Pract"},{"key":"4922_CR8","doi-asserted-by":"publisher","unstructured":"Alagiyawanna L, Prince S, Wright D, Clarke E (2021) Temozolomide hypersensitivity-A story of success. Neurooncology 23(4). https:\/\/doi.org\/10.1093\/neuonc\/noab195.047. p. iv18-iv19","DOI":"10.1093\/neuonc\/noab195.047"},{"issue":"1","key":"4922_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00280-025-04782-9","volume":"95","author":"ME Cantley","year":"2025","unstructured":"Cantley ME, Coleman C, Morgan RM, Reddy N, Sertich SA, Villano JL (2025) Novel desensitization protocol utilizing conventional formulations to mitigate Temozolomide-Related skin hypersensitivity. Cancer Chemother Pharmacol 95(1):61. https:\/\/doi.org\/10.1007\/s00280-025-04782-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"4922_CR10","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/j.anai.2023.08.350","volume":"131","author":"R Balijepally","year":"2023","unstructured":"Balijepally R, Zheng J, Taylor J, Otani I (2023) OUTPATIENT TEMOZOLOMIDE DESENSITIZATION UTILIZING COMMERCIALLY AVAILABLE CAPSULES. Annals of Allergy. Asthma Immunol 131(5):S118. https:\/\/doi.org\/10.1016\/j.anai.2023.08.350","journal-title":"Asthma Immunol"},{"issue":"2","key":"4922_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jaci.2004.04.029","volume":"114","author":"SG Brown","year":"2004","unstructured":"Brown SG (2004) Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 114(2):371\u2013376. https:\/\/doi.org\/10.1016\/j.jaci.2004.04.029","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"4922_CR12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jaip.2015.12.007","volume":"4","author":"R Divekar","year":"2016","unstructured":"Divekar R, Butterfield J, Maddox D (2016) Successful rapid desensitization to temozolomide: A case series. J Allergy Clin Immunol Pract 4(3):545\u2013546. https:\/\/doi.org\/10.1016\/j.jaip.2015.12.007","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"4922_CR13","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.anai.2011.02.009","volume":"106","author":"RG M\u00f3nica","year":"2011","unstructured":"M\u00f3nica RG, De Las Heras Gozalo M, de la Barrera EH, Dominguez JS (2011) Successful desensitization with temozolomide. Ann Allergy Asthma Immunol 106(6):541\u2013542. https:\/\/doi.org\/10.1016\/j.anai.2011.02.009","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"4922_CR14","first-page":"448","volume":"22","author":"A Alonso-Llamazares","year":"2012","unstructured":"Alonso-Llamazares A, Vega-Castro A, Beitia-Mazuecos JM, Mateo-Borrega B, Cardenas-Contreras R (2012) Rapid desensitization with temozolomide in patients with delayed maculopapular rash. J Investig Allergol Clin Immunol 22(6):448\u2013449","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"5","key":"4922_CR15","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jaip.2014.03.016","volume":"2","author":"E Clayton","year":"2014","unstructured":"Clayton E, Madamba J, Kong XT, Braskett M (2014) Successful desensitization protocol for delayed cutaneous eruption to temozolomide. J Allergy Clin Immunol Pract 2(5):626\u2013628. https:\/\/doi.org\/10.1016\/j.jaip.2014.03.016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"4922_CR16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00280-020-04123-y","volume":"86","author":"BJ Neth","year":"2020","unstructured":"Neth BJ, Ruff MW, Uhm JH, Johnson DR, Divekar RD, Maddox DE (2020) Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity. Cancer Chemother Pharmacol 86(3):375\u2013382. https:\/\/doi.org\/10.1007\/s00280-020-04123-y","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"4922_CR17","first-page":"1142","volume":"9","author":"S Pothiawala","year":"2010","unstructured":"Pothiawala S, Hsu MY, Yang C, Kesari S, Ibrahimi OA (2010) Urticarial hypersensitivity reaction caused by temozolomide. J Drugs Dermatol 9(9):1142\u20131144","journal-title":"J Drugs Dermatol"},{"key":"4922_CR18","first-page":"2063","volume":"9","author":"C Calabr\u00f2","year":"2024","unstructured":"Calabr\u00f2 C, F C, Ferraiuolo, Laforgia S, Vincenti M, Ungaro A, Nardulli V (2024) Castell\u2019s rapid desensitization as a major therapeutic opportunity for patients experiencing hypersensitivity reactions to antiblastic drugs. Clin Oncol 9:2063","journal-title":"Clin Oncol"},{"key":"4922_CR19","doi-asserted-by":"publisher","first-page":"590991","DOI":"10.3389\/fphar.2020.590991","volume":"11","author":"A Vultaggio","year":"2020","unstructured":"Vultaggio A, Matucci A, Nencini F, Bormioli S, Vivarelli E, Maggi E (2020) Mechanisms of Drug Desensitization: Not Only Mast Cells. Front Pharmacol 11:590991. https:\/\/doi.org\/10.3389\/fphar.2020.590991","journal-title":"Front Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04922-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04922-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04922-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:43:51Z","timestamp":1783399431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04922-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4922"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04922-9","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}